Literature DB >> 25741862

The importance of an integrated analysis of clinical, molecular, and functional data for the genetic diagnosis of familial hypercholesterolemia.

Asier Benito-Vicente1, Ana Catarina Alves2,3, Aitor Etxebarria1, Ana Medeiros Medeiros2,3, Cesar Martin1, Mafalda Bourbon2,3.   

Abstract

PURPOSE: Familial hypercholesterolemia (FH) is one of the most common monogenic disorders, and the high concentrations of low-density lipoprotein (LDL) cholesterol presented since birth confers on these patients an increased cardiovascular risk. More than 1,600 alterations have been described in the LDL receptor gene (LDLR), but a large number need to be validated as mutations causing disease to establish a diagnosis of FH. This study aims to characterize, both at the phenotypic and genotypic levels, families with a clinical diagnosis of FH and present evidence for the importance of the integration of clinical, molecular, and functional data for the correct diagnosis of patients with FH.
METHODS: A detailed analysis of the phenotype and genotype presented by 55 families with 13 different alterations in the LDLR was conducted. For eight of these, an extensive functional characterization was performed by flow cytometry, confocal microscopy, and reverse transcriptase polymerase chain reaction.
RESULTS: Carriers of neutral alterations presented a significantly lower incidence of premature cardiovascular disease, lower levels of atherogenic lipoproteins and a large number of these individuals had LDL-cholesterol values below the 75(th) percentile. presented a significantly lower incidence of premature cardiovascular disease, lower levels of atherogenic lipoproteins and a large number of these individuals had LDL-cholesterol values below the 75th percentile However, the functional study was essential to determine the pathogenicity of variants.
CONCLUSION: The data collected illustrate the importance of this integrated analysis for the correct assessment of patients with FH who can otherwise be misdiagnosed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25741862     DOI: 10.1038/gim.2015.14

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  36 in total

1.  The molecular basis of familial hypercholesterolemia in The Netherlands.

Authors:  S W Fouchier; J C Defesche; M W Umans-Eckenhausen; J P Kastelein
Journal:  Hum Genet       Date:  2001-11-09       Impact factor: 4.132

2.  [Lipid profile of the Spanish population: the DRECE (diet and risk of cardiovascular disease in Spain) study. DRECE study group].

Authors:  J A Gómez-Gerique; J A Gutiérrez-Fuentes; M T Montoya; A Porres; A Rueda; A Avellaneda; M A Rubio
Journal:  Med Clin (Barc)       Date:  1999-12-04       Impact factor: 1.725

3.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Authors:  Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood
Journal:  Eur Heart J       Date:  2011-06-28       Impact factor: 29.983

4.  Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing.

Authors:  Steve E Humphries; Treena Cranston; Marcus Allen; Helen Middleton-Price; Maryam C Fernandez; Victoria Senior; Emma Hawe; Andrew Iversen; Richard Wray; Martin A Crook; Anthony S Wierzbicki
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

5.  Recurrent and novel LDL receptor gene mutations causing heterozygous familial hypercholesterolemia in La Habana.

Authors:  E Pereira; R Ferreira; B Hermelin; G Thomas; C Bernard; V Bertrand; H Nassiff; D Mendez del Castillo; G Bereziat; P Benlian
Journal:  Hum Genet       Date:  1995-09       Impact factor: 4.132

6.  Splice site prediction in Arabidopsis thaliana pre-mRNA by combining local and global sequence information.

Authors:  S M Hebsgaard; P G Korning; N Tolstrup; J Engelbrecht; P Rouzé; S Brunak
Journal:  Nucleic Acids Res       Date:  1996-09-01       Impact factor: 16.971

7.  Molecular characterization of familial hypercholesterolemia in Spain: identification of 39 novel and 77 recurrent mutations in LDLR.

Authors:  Pilar Mozas; Sergio Castillo; Diego Tejedor; Gilberto Reyes; Rodrigo Alonso; Miguel Franco; Pedro Saenz; Francisco Fuentes; Fátima Almagro; Pedro Mata; Miguel Pocoví
Journal:  Hum Mutat       Date:  2004-08       Impact factor: 4.878

8.  Standardization of a flow cytometric method for measurement of low-density lipoprotein receptor activity on blood mononuclear cells.

Authors:  K Løhne; P Urdal; T P Leren; S Tonstad; L Ose
Journal:  Cytometry       Date:  1995-08-01

9.  Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment.

Authors:  Ebele Usifo; Sarah E A Leigh; Ros A Whittall; Nicholas Lench; Alison Taylor; Corin Yeats; Christine A Orengo; Andrew C R Martin; Jacopo Celli; Steve E Humphries
Journal:  Ann Hum Genet       Date:  2012-09       Impact factor: 1.670

10.  Functional analysis of four LDLR 5'UTR and promoter variants in patients with familial hypercholesterolaemia.

Authors:  Amna Khamis; Jutta Palmen; Nick Lench; Alison Taylor; Ebele Badmus; Sarah Leigh; Steve E Humphries
Journal:  Eur J Hum Genet       Date:  2014-09-24       Impact factor: 4.246

View more
  16 in total

1.  A Novel Modified System of Simplified Chinese Criteria for Familial Hypercholesterolemia (SCCFH).

Authors:  Ye-Xuan Cao; Di Sun; Hui-Hui Liu; Jing-Lu Jin; Sha Li; Yuan-Lin Guo; Na-Qiong Wu; Cheng-Gang Zhu; Ying Gao; Qiu-Ting Dong; Geng Liu; Qian Dong; Jian-Jun Li
Journal:  Mol Diagn Ther       Date:  2019-08       Impact factor: 4.074

2.  Mutational analysis of a cohort with clinical diagnosis of familial hypercholesterolemia: considerations for genetic diagnosis improvement.

Authors:  Ana Margarida Medeiros; Ana Catarina Alves; Mafalda Bourbon
Journal:  Genet Med       Date:  2015-05-28       Impact factor: 8.822

3.  The UCL low-density lipoprotein receptor gene variant database: pathogenicity update.

Authors:  Sarah Leigh; Marta Futema; Ros Whittall; Alison Taylor-Beadling; Maggie Williams; Johan T den Dunnen; Steve E Humphries
Journal:  J Med Genet       Date:  2016-11-07       Impact factor: 6.318

Review 4.  Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants.

Authors:  Asier Benito-Vicente; Kepa B Uribe; Shifa Jebari; Unai Galicia-Garcia; Helena Ostolaza; Cesar Martin
Journal:  Int J Mol Sci       Date:  2018-06-05       Impact factor: 5.923

5.  p.(Asp47Asn) and p.(Thr62Met): non deleterious LDL receptor missense variants functionally characterized in vitro.

Authors:  A Benito-Vicente; H Siddiqi; K B Uribe; S Jebari; U Galicia-Garcia; A Larrea-Sebal; M Stef; H Ostolaza; L Palacios; C Martin
Journal:  Sci Rep       Date:  2018-11-09       Impact factor: 4.379

6.  Therapeutic targets of hypercholesterolemia: HMGCR and LDLR.

Authors:  Shizhan Ma; Wenxiu Sun; Ling Gao; Shudong Liu
Journal:  Diabetes Metab Syndr Obes       Date:  2019-08-21       Impact factor: 3.168

7.  Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity.

Authors:  Poulabi Banerjee; Kuo-Chen Chan; Michel Tarabocchia; Asier Benito-Vicente; Ana C Alves; Kepa B Uribe; Mafalda Bourbon; Paul J Skiba; Robert Pordy; Daniel A Gipe; Daniel Gaudet; Cesar Martin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-10-03       Impact factor: 8.311

8.  Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis.

Authors:  Joana Rita Chora; Ana Margarida Medeiros; Ana Catarina Alves; Mafalda Bourbon
Journal:  Genet Med       Date:  2017-10-26       Impact factor: 8.822

9.  Replacement of cysteine at position 46 in the first cysteine-rich repeat of the LDL receptor impairs apolipoprotein recognition.

Authors:  A Benito-Vicente; K B Uribe; H Siddiqi; S Jebari; U Galicia-Garcia; A Larrea-Sebal; A Cenarro; M Stef; H Ostolaza; F Civeira; L Palacios; C Martin
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

Review 10.  Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease.

Authors:  Asier Benito-Vicente; Kepa B Uribe; Shifa Jebari; Unai Galicia-Garcia; Helena Ostolaza; Cesar Martin
Journal:  Int J Mol Sci       Date:  2018-11-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.